NCT04460105View on ClinicalTrials.gov

Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

October 31, 2020

Primary Completion Date

January 27, 2021

Study Completion Date

January 27, 2021

Conditions

COVID-19 Pneumonia

Interventions

DRUG

Lanadelumab

Participants will receive 300 mg of lanadelumab IV infusion on Day 1 and Day 4.

OTHER

Placebo

Participants will receive placebo matching IV infusion on Day 1 and Day 4.

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

lead

Shire

INDUSTRY

NCT04460105 - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter